Characterization of residual kidney function in chronic hemodialysis patients using plasma metabolomics

Huijben, J. A. et al. Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: An ERA Registry study. Nephrol. Dial. Transplant. 38, 1027–1040 (2022). 10.1093/ndt/gfac165

[3]

The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparisons

Rianne Boenink, Marjolein Bonthuis, Brittany A Boerstra et al.

Clinical Kidney Journal 2025 10.1093/ckj/sfae405

[4]

Shafi, T. et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 56, 348–358 (2010). 10.1053/j.ajkd.2010.03.020

[5]

Obi, Y. et al. Residual kidney function decline and mortality in incident hemodialysis patients. J. Am. Soc. Nephrol. 27, 3758–3768 (2016). 10.1681/asn.2015101142

[6]

Wong, M. M. Y. et al. Interdialytic weight gain: Trends, predictors, and associated outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 69, 367–379 (2017). 10.1053/j.ajkd.2016.08.030

[7]

Cheung, A. K. et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J. Am. Soc. Nephrol. JASN 17, 546–555 (2006). 10.1681/asn.2005020132

[8]

Leong, S. C. et al. Residual function effectively controls plasma concentrations of secreted solutes in patients on twice weekly hemodialysis. J. Am. Soc. Nephrol. 29, 1992 (2018). 10.1681/asn.2018010081

[9]

Hemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood Flow

Christopher W. McIntyre, James O. Burton, Nicholas M. Selby et al.

Clinical Journal of the American Society of Nephro... 2008 10.2215/cjn.03170707

[10]

Renal Perfusion during Hemodialysis: Intradialytic Blood Flow Decline and Effects of Dialysate Cooling

Raanan Marants, Elena Qirjazi, Claire J. Grant et al.

Journal of the American Society of Nephrology 2019 10.1681/asn.2018121194

[11]

Polinder-Bos, H. A. et al. Hemodialysis induces an acute decline in cerebral blood flow in elderly patients. J. Am. Soc. Nephrol. JASN 29, 1317–1325 (2018). 10.1681/asn.2017101088

[12]

Jaques, D. A. et al. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis. Nephrol. Dial. Transplant. 37, 2514–2521 (2022). 10.1093/ndt/gfac205

[13]

Rhee, E. P. et al. Metabolite profiling identifies markers of uremia. J. Am. Soc. Nephrol. JASN 21, 1041–1051 (2010). 10.1681/asn.2009111132

[14]

Shah, V. O. et al. Plasma metabolomic profiles in different stages of CKD. Clin. J. Am. Soc. Nephrol. CJASN 8, 363–370 (2013). 10.2215/cjn.05540512

[15]

Gagnebin, Y. et al. Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics. Sci. Rep. 10, 19502 (2020). 10.1038/s41598-020-76524-1

[16]

Obi, Y., Kalantar-Zadeh, K., Streja, E. & Daugirdas, J. T. Prediction equation for calculating residual kidney urea clearance using urine collections for different hemodialysis treatment frequencies and interdialytic intervals. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 33, 530–539 (2018).

[17]

KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update

John T. Daugirdas, Thomas A. Depner, Jula Inrig et al.

American Journal of Kidney Diseases 2015 10.1053/j.ajkd.2015.07.015

[18]

Watson, P. E., Watson, I. D. & Batt, R. D. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am. J. Clin. Nutr. 33, 27–39 (1980). 10.1093/ajcn/33.1.27

[19]

Daugirdas, J. T. et al. Improved equation for estimating single-pool Kt/V at higher dialysis frequencies. Nephrol. Dial. Transplant. 28, 2156–2160 (2013). 10.1093/ndt/gfs115

[20]

Tattersall, J. E., DeTakats, D., Chamney, P., Greenwood, R. N. & Farrington, K. The post-hemodialysis rebound: Predicting and quantifying its effect on Kt/V. Kidney Int. 50, 2094–2102 (1996). 10.1038/ki.1996.534

[21]

Leypoldt, J. K., Jaber, B. L. & Zimmerman, D. L. Daily hemodialysis—selected topics: Predicting treatment dose for novel therapies using urea standard Kt/V. Semin. Dial. 17, 142–145 (2004). 10.1111/j.0894-0959.2004.17212.x

[22]

Vanholder, R., Pletinck, A., Schepers, E. & Glorieux, G. Biochemical and clinical impact of organic uremic retention solutes: A comprehensive update. Toxins 10, 33 (2018). 10.3390/toxins10010033

[23]

Ganesan, L. L. et al. Association of plasma uremic solute levels with residual kidney function in children on peritoneal dialysis. Clin. J. Am. Soc. Nephrol. CJASN 16, 1531–1538 (2021). 10.2215/cjn.01430121

[24]

Pawlak, K., Kowalewska, A., Mysliwiec, M. & Pawlak, D. 3-Hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease. Clin. Biochem. 43, 1101–1106 (2010). 10.1016/j.clinbiochem.2010.06.008

[25]

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

Zeneng Wang, Elizabeth Klipfell, Brian J. Bennett et al.

Nature 2011 10.1038/nature09922

[26]

Gagnebin, Y. et al. Toward a better understanding of chronic kidney disease with complementary chromatographic methods hyphenated with mass spectrometry for improved polar metabolome coverage. J. Chromatogr. B. 1116, 9–18 (2019). 10.1016/j.jchromb.2019.03.031

[27]

Olesti, E. et al. Low-polarity untargeted metabolomic profiling as a tool to gain insight into seminal fluid. Metabolomics 19, 53 (2023). 10.1007/s11306-023-02020-y

[28]

Masereeuw, R. et al. The kidney and uremic toxin removal: Glomerulus or tubule?. Semin. Nephrol. 34, 191–208 (2014). 10.1016/j.semnephrol.2014.02.010

[29]

van Gelder, M. K. et al. Protein-bound uremic toxins in hemodialysis patients relate to residual kidney function, are not influenced by convective transport, and do not relate to outcome. Toxins 12, 234 (2020). 10.3390/toxins12040234

[30]

Ren, Y. et al. Altered gut mycobiome in patients with end-stage renal disease and its correlations with serum and fecal metabolomes. J. Transl. Med. 22, 202 (2024). 10.1186/s12967-024-05004-1

[31]

Muteliefu, G., Enomoto, A. & Niwa, T. Indoxyl sulfate promotes proliferation of human aortic smooth muscle cells by inducing oxidative stress. J. Ren. Nutr. 19, 29–32 (2009). 10.1053/j.jrn.2008.10.014

[32]

Tumur, Z., Shimizu, H., Enomoto, A., Miyazaki, H. & Niwa, T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am. J. Nephrol. 31, 435–441 (2010). 10.1159/000299798

[33]

Toth-Manikowski, S. M. et al. Contribution of ‘clinically negligible’ residual kidney function to clearance of uremic solutes. Nephrol. Dial. Transplant. 35, 846–853 (2019). 10.1093/ndt/gfz042

[34]

Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms

J. C. Schefold, J.-P. Zeden, C. Fotopoulou et al.

Nephrology Dialysis Transplantation 2009 10.1093/ndt/gfn739

[35]

Sulo, G. et al. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int. J. Cardiol. 168, 1435–1440 (2013). 10.1016/j.ijcard.2012.12.090

[36]

Wirleitner, B. et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur. J. Clin. Invest. 33, 550–554 (2003). 10.1046/j.1365-2362.2003.01186.x

[37]

Pawlak, K., Myśliwiec, M. & Pawlak, D. Kynurenine pathway - A new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv. Med. Sci. 55, 196–203 (2010). 10.2478/v10039-010-0015-6

[38]

Konje, V. C. et al. Tryptophan levels associate with incident cardiovascular disease in chronic kidney disease. Clin. Kidney J. 14, 1097–1105 (2021). 10.1093/ckj/sfaa031

[39]

Miao, H. et al. Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites. Br. J. Pharmacol. 181, 162–179 (2024). 10.1111/bph.16219

[40]

Miao, H. et al. Targeting Lactobacillus johnsonii to reverse chronic kidney disease. Signal Transduct. Target. Ther. 9, 195 (2024). 10.1038/s41392-024-01913-1

[41]

Zhang, Q. et al. Metabolomic profiling reveals the step-wise alteration of bile acid metabolism in patients with diabetic kidney disease. Nutr. Diabetes 14, 85 (2024). 10.1038/s41387-024-00315-0

[42]

Gan, L., Wang, L., Li, W., Zhang, Y. & Xu, B. Metabolomic profile of secondary hyperparathyroidism in patients with chronic kidney disease stages 3–5 not receiving dialysis. Front. Endocrinol. 15, 1406690 (2024). 10.3389/fendo.2024.1406690

[43]

Casino, F. G. et al. The reasons for a clinical trial on incremental haemodialysis. Nephrol. Dial. Transplant. 35, 2015–2019 (2020). 10.1093/ndt/gfaa220

[44]

Casino, F. G. & Basile, C. The variable target model: A paradigm shift in the incremental haemodialysis prescription. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 32, 182–190 (2017).

[45]

Fry, A. C., Singh, D. K., Chandna, S. M. & Farrington, K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif. 25, 295–302 (2007). 10.1159/000104870

[46]

Miler, M. & Simundić, A.-M. Low level of adherence to instructions for 24-hour urine collection among hospital outpatients. Biochem. Med. 23, 316–320 (2013). 10.11613/bm.2013.038

[47]

Jaques, D. A. & Davenport, A. Serum β2-microglobulin as a predictor of residual kidney function in peritoneal dialysis patients. J. Nephrol. 34, 473–481 (2021). 10.1007/s40620-020-00906-x

[48]

Shafi, T. et al. Estimating residual kidney function in dialysis patients without urine collection. Kidney Int. 89, 1099–1110 (2016). 10.1016/j.kint.2015.10.011

[49]

Wong, J. et al. Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin. Kidney Int. 89, 1090–1098 (2016). 10.1016/j.kint.2015.12.042

[50]

Mandal, R. et al. Comprehensive, quantitative analysis of SRM 1950: The NIST human plasma reference material. Anal. Chem. 97, 667–675 (2025). 10.1021/acs.analchem.4c05018

Showing 50 of 51 references

Metrics

0

Citations

51

References

Details

Published: Apr 07, 2026
Vol/Issue: 16(1)
License: View

Authors

D

David A. Jaques

Division of Nephrology and Hypertension Geneva University Hospitals Geneva Switzerland

Valérie Jotterand Drepper

Department of Nephrology Geneva University Hospital, Geneva, Switzerland

Division of Nephrology, University Hospital, Zurich, Switzerland

S

Sophie de Seigneux

Laboratory of Nephrology, Service of Nephrology, Departments of Internal Medicine Specialties and Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland

Cite This Article

David A. Jaques, Julien Boccard, Oriane Strassel, et al. (2026). Characterization of residual kidney function in chronic hemodialysis patients using plasma metabolomics. Scientific Reports, 16(1). https://doi.org/10.1038/s41598-026-47357-1

Characterization of residual kidney function in chronic hemodialysis patients using plasma metabolomics

You May Also Like